| Prev Close | 268.35 |
| Open | 265.51 |
| Day Low/High | 263.78 / 268.00 |
| 52 Wk Low/High | 176.36 / 292.75 |
| Volume | 481.17K |
Vertex Pharmaceuticals Incorporated (VRTX)
266.42
1.90
0.72
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 255.76B |
| Market Cap | 66.14B |
| P/E Ratio | 23.27 |
| Div & Yield | N.A. (N.A) |
The 5 Dumbest Things on Wall Street: June 1
Here is this week's roundup of the dumbest actions on Wall Street.
Slow, but Positive
The longer this action persists, the more anxious folks will be to put idle cash to work.
Biotech Breakout
SPDR S&P Biotech ETF is likely to post new highs in the second quarter.
Daily Recap of the Charts, May 7
Evan Lazarus of T3Live review the day's market action and sets up your trading plan for the next session.
The Next Big Thing in Biotech: Pfizer
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
Looking for a Blaze of Markups
Here are a couple of window-dressing plays as we head into the end of the quarter.
Be Ready for Surprises
Earnings season is well upon us, so better to be prepared than, well, taken by surprise.
Divining the Earnings Winners
Based on patterns of estimates revisions, these names might just generate some magic when they report.
Looking at Four Biotechs
Here is my take on some questions from readers.
Don't Ignore Earnings Plays
Because of Europe, the market has turned a deaf ear toward earnings season.
Forget About Europhoria
The euro/dollar cross foretold yesterday's big rally, but individual stocks' action amid the broad upswing could be telling.
Playing Vertex Into Earnings
The chart and the CEO tell very different stories about the drugmaker. Which one is right?
